Undesirable effects are listed by MedDRA System Organ Classes.
Assessment of undesirable effects is based on the following frequency groupings:
Very common: ≥ 1/10
Common: ≥ 1/100 to <1/10
Uncommon: ≥ 1/1,000 to <1/100
Rare: ≥ 1/10,000 to <1/1,000
Very rare: <1/10,000
Not known: cannot be estimated from the available data
System Organ Class | Undesirable Effect | Frequency |
Skin and subcutaneous tissue disorders | skin irritation* | Not known |
Injury, poisoning and procedural complications | salicylism (including tinnitus) | Not known |
* A localised irritant reaction may occur if Occlusal is applied to normal skin surrounding the wart. This may normally be controlled by temporarily discontinuing the use of Occlusal and by being careful to apply the solution only to the wart itself when treatment is resumed.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.